SCHEDULE: Alpha Capital Anstalt Boosts Qualigen Stake to 9.06%

Alpha Capital Anstalt has reported a 9.056% beneficial ownership stake in Qualigen Therapeutics, Inc., holding 153,545 shares of common stock.

Summary

• Alpha Capital Anstalt reported beneficial ownership of 153,545 shares of Qualigen Therapeutics, Inc. common stock.
• This represents 9.056% of the company's outstanding common stock.
• The percentage is based on 1,695,450 shares outstanding as of September 22, 2025, as reported in a DEF-14A filing on October 20, 2025.
• Alpha Capital Anstalt holds sole voting and dispositive power over all 153,545 shares.
• The securities were not acquired for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 7

Explanation: Alpha Capital Anstalt's disclosure of a 9.056% beneficial ownership stake in Qualigen Therapeutics, Inc. suggests a notable level of confidence from an institutional investor. While the filing explicitly states the shares were not acquired for the purpose of changing or influencing control, a substantial passive stake can still be viewed positively by the market as it indicates a belief in the company's underlying value or future prospects.

Positives

• A significant institutional investor, Alpha Capital Anstalt, holds a substantial 9.056% stake, indicating confidence in Qualigen Therapeutics, Inc.
• The investor explicitly states the holding is not for control influence, suggesting a passive investment strategy focused on long-term value.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor holding a nearly 10% stake could be perceived positively, potentially boosting investor confidence and signaling a belief in the company's value.
• Management: Awareness of a large, passive institutional holder may influence management's strategic decisions, though the filing states no intent to influence control.

Key Dates

Recommendation

The filing indicates a significant institutional stake, which can be a positive signal. However, a Schedule 13G filing primarily reports ownership and does not provide operational or financial performance details of Qualigen Therapeutics, Inc. Without further information on the company's fundamentals, strategic direction, or recent financial results, a "hold" recommendation is prudent. The presence of a large institutional investor suggests potential underlying value, but a deeper dive into the company's business is required for a stronger recommendation.

Keywords

Qualigen Therapeutics, Alpha Capital Anstalt, Beneficial Ownership, Common Stock, SEC Filing, Schedule 13G, Institutional Investor